Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Aggiungi a watchlist

53,09

+0,15

(+0,28%)

Alla chiusura: 04:00PM EDT

53,10

+0,01

(+0,02%)

Dopo ore:

06:21PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	11,921B
Beta (5 anni mensile)	0,67
Rapporto PE (ttm)	16,09
EPS (ttm)	3,30
Prossima data utili	30 lug 2024 - 05 ago 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	72,41

Tutte

GlobeNewswire
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswire
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto